Loading
Life sciences · Journal article
Pharmaceuticals · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Objectives: Fibroblast activation protein (FAP) represents an attractive target for both cancer imaging and radionuclide therapy. Nevertheless, the prolonged retention of many FAP-targeting inhibitors within tumor tissue remains challenging. Therefore, we investigated FAPi-mFS, an FAP inhibitor derived from FAPi-04 that carries a fluorosulfate warhead in meta position. This structural feature was designed to enable a predominantly irreversible covalent binding to FAP, thereby improving tumor retention time. Methods: [68Ga]Ga-FAPi-mFS and [177Lu]Lu-FAPi-mFS were successfully synthesized for large-scale clinical use by radiolabeling FAPi-mFS under validated conditions. The radiochemical conversion, yield, purity and stability were evaluated using radio-thin-layer chromatography (TLC), radio-high-performance liquid chromatography (HPLC), and in vitro human serum stability tests. Results: In the radiolabeling experiments, reproducibly high radiochemical purities of over 96% were achieved for both nuclides, along with decay-corrected yields of over 90% for gallium-68 (Ga-68) and over 80% for lutetium-177 (Lu-177) for batch sizes for Lu-177 up to 50 GBq. Both radiopharmaceuticals exhibited high in vitro stability with minimal release of Ga-68 (<1%) over 90 min and Lu-177 (<11%) over two physical half-lives. Conclusions: FAPi-mFS can be efficiently labeled with both Ga-68 and Lu-177 with high purity and stability using clinically applicable procedures. As a covalent FAP inhibitor, FAPi-mFS represents a promising strategy for prolonging retention time in tumors and potentially enhancing the therapeutic efficacy of FAP-specific radiopharmaceuticals.